0.20Open0.20Pre Close0 Volume184 Open Interest7.50Strike Price0.00Turnover867.91%IV587.50%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.3316Delta0.2074Gamma5.60Leverage Ratio-0.0269Theta0.0001Rho1.86Eff Leverage0.0007Vega
Omega Therapeutics Stock Discussion
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
Omega Therapeutics (Nasdaq: OMGA) has published preclinical data for OTX-2002, their epigenomic controller targeting the MYC gene in hepatocellular carcinoma (HCC), in Nature Communications. The study demonstrates OTX-2002's ability to downregulate MYC expression and inhibit tumor growth in HCC models, both as a monotherapy and in combination wi...
NEWS
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
Investors Rethink Rate Cut Bets
US equities ended Friday slightly higher, but gains weren't enough to keep major indices in the green in the first trading week of the year. The stock market ended their nine-week winning streak as investors rethink bets of aggressive interest rate cuts this year amid signs of continued strength in the labor market.
The $S&P 500 Index (.SPX.US)$ rose 0.2% to close at 4,697.24 Friday, while the $Nasdaq Composite Index (.IXIC.US)$ rose less...
Omega shares almost doubled Thursday after the company said its flagship’s Pioneering Medicines initiative, and Novo Nordisk will jointly advance an obesity management program through preclinical development and...
No comment yet